MENLO PARK, Calif.--(BUSINESS WIRE)--June 26, 2006--Depomed, Inc. (Nasdaq:DEPO - News) announced today that results from two studies of Gabapentin GR support the ability of its improved, extended release formulation to achieve dose-proportional absorption of the pain drug, gabapentin. Gabapentin GR extended release tablets are in development for the treatment of postherpetic neuralgia (PHN), a long lasting pain condition caused by nerve damage during a shingles, or herpes zoster, viral infection. The data were reported at the Endocrine Society's Annual Meeting taking place in Boston.
